Company overview
Prolacta Bioscience is a privately held, global life sciences company dedicated to Advancing the Science of Human Milk to improve the health of premature and critically ill infants. Prolacta's 100% human milk–based nutritional products have been evaluated in more than 20 clinical studies published in peer-reviewed journals. More than 100,000 premature infants have benefited from Prolacta’s nutritional products worldwide to-date.*
Established in 1999, Prolacta is the world’s leading provider of human milk–based nutritional products for hospital use and is also exploring the therapeutic potential of human milk across a wide spectrum of diseases. Prolacta maintains the industry’s strictest quality and safety standards for screening, testing, and processing human donor milk.
Operating the world’s first pharmaceutical-grade human milk processing facilities, Prolacta uses vat pasteurization and a patented, FDA-reviewed manufacturing process to ensure pathogen inactivation, while protecting the nutritional composition and bioactivity of its human milk–based products.1,2 Prolacta is a global company with headquarters in Duarte, California.
Media contact
Loren Kosmont
lkosmont@prolacta.com
310.721.9444
*Estimated number of premature infants fed Prolacta’s products from January 2007 to August 2023; data on file.
Assets
For photos and B-roll video, contact lkosmont@prolacta.com.
Press + news
See all- Press releases
- Prolacta in the news
Prolacta Bioscience neonatologist Dr. Erin Hamilton Spence earns breastfeeding and lactation medicine certification held by fewer than 100 North American physicians
FDA approves first human milk-based fortifier for term infants to support growth and recovery following surgery for Gastroschisis
Study finds fewer cases of Necrotizing Enterocolitis in premature infants and cost savings after implementing an Exclusive Human Milk Diet
Study shows vat pasteurization outperforms other methods in preserving human milk’s native bioactive properties
Hot Topics in Neonatology® 2024 Conference to feature symposium on clinical impact & cost savings of an Exclusive Human Milk Diet
Prolacta celebrates advancements in neonatal care during Prematurity Awareness Month
Humavant® 100% human milk-based fortifiers helping premature infants in Australia grow and develop
Prolacta Bioscience appoints Dr. Sandra Sullivan as director of clinical education and professional development
Prolacta Bioscience applauds new California state law expanding access to donor human milk for fragile infants
More than 50% of level III & IV NICUs in U.S. used Prolacta's 100% human milk-based products to help reduce Necrotizing Enterocolitis (NEC) in the smallest premature infants in 2024
Prolacta Bioscience applauds passage of the maternal health bill in Massachusetts
Working to address equity in premature nutrition, National Black Nurses Association and Prolacta Bioscience support H.R. 7141
Preterm infant study finds proactive use of Prolact CR cream improves growth and reduces NICU costs
Prolacta Bioscience demonstrates leadership in human milk science with history of voluntarily reviewing health claims with the FDA
Study shows exclusive human milk diet benefits term infants post-gastroschisis repair; Data to be presented at ESPGHAN 2024 meeting
Pediatric Academic Societies Meeting includes symposium on cost-effectiveness of implementing exclusive human milk-based nutrition for premature infants
Novel research illuminates breast milk’s unique contribution to COVID-19 defense in infants
Real-world data on human milk-based fortification reveals limitations of protocol designs of two RCTs
Prolacta's human milk-based nutrition has touched the lives of 100,000 Premature and Critically Ill Infants Globally
Prolacta Bioscience applauds Ohio legislature for supporting Medicaid reimbursement for donor human milk-derived products
Prolacta Bioscience recognizes advances in preterm care during NICU awareness month
Study reveals Prolacta’s 100% human milk-based nutritional fortifiers significantly increase bioactive proteins and antioxidant activity in human milk samples, outperforming cow milk-based fortifier
New study shows Prolacta’s human milk-based nutritional fortifiers save hospital NICUs up to $3.4M annually
Prolacta Bioscience celebrates donor moms on World Human Milk Donation Day
Prolacta Bioscience recognizes contributions of breast milk donors during National Nutrition Month
.jpg){kind=link}
